Primary aldosteronism

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 4, 2003, Pages 591-605

  Stowasser, Michael ^a   Gordon, Richard D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diagnosis; Fam ilial; Genetics; Hyperaldosteronism; Hypertension; Prevalence; Primary aldosteronism; Screening; Treatment

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DEXAMETHASONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FLUDROCORTISONE ACETATE; GLUCOCORTICOID; HYDRALAZINE; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHLORIDE; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; PREDNISOLONE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; VERAPAMIL;

ADENOMA; ADRENAL BLOOD FLOW; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; BIOCHEMISTRY; BLOOD SAMPLING; BODY POSTURE; CLINICAL FEATURE; CUSHINGOID SYNDROME; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; FAMILIAL DISEASE; FAMILIAL HYPERALDOSTERONISM I; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GROWTH RETARDATION; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; LABORATORY DIAGNOSIS; LIBIDO DISORDER; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; PATHOGENESIS; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCREENING; SODIUM INTAKE; VENOUS BLOOD; ADRENAL GLAND;

EID: 0345170995     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00050-2     Document Type: Review

References (86)

1. Simpson SA, Tait JF, Wettstein A et al. Konstitution des aldosterons, des neuen mineralocorticoids. Experientia 1954; 10: 132-133.
2. Conn JW. Primary aldosteronism, a new clinical syndrome. Journal of Laboratory and Clinical Medicine 1955; 45: 6-17.
3. Conn JW. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. Journal of the American Medical Association 1964; 100: 222-225.
4. Kaplan NM. Commentary on the incidence of primary aldosteronism. Current estimations based on objective data. Archives of Internal Medicine 1969; 123: 152-155.
5. Biglieri EG & Kater CE. Disorders of the adrenal cortex. In Stein JH (ed.) Internal Medicine, 3rd edn. Boston: Little Brown, 1991, pp 2188-2207.
6. Gordon RD, Klemm SA, Tunny TJ & Stowasser M. Primary aldosteronism: Hypertension with a genetic basis. Lancet 1992; 340: 159-161.
7. Gordon RD, Stowasser M, Klemm SA & Tunny TJ. Primary aldosteronism and other forms of mineralocorticoid hypertension. In Swales J (ed.) Textbook of Hypertension. London: Blackwell Scientific, 1994, pp 865-892.
8. Young Jr WF. Primary aldosteronism: Update on diagnosis and treatment. Endocrinologist 1997; 7: 213-221.
9. Lim PO, Rodgers P, Cardale K et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40.
10. Loh K-C, Koay E-S, Khaw M-C et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. Journal of Clinical Endocrinology and Metabolism 2000; 85: 2854-2859.
11. Rayner BL, Opie LH & Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. South African Medical Journal 2000; 90: 394-400.
12. Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary aldosteronism in essential hypertensives: Prevalence, biochemical profile and molecular biology. Journal of Clinical Endocrinology and Metabolism 2000; 85: 1863-1867.
13. Celen O, O'Brien MJ & Melby JC. Factors influencing outcome of surgery for primary aldosteronism. Archives of Surgery 1996; 131: 646-650.
14. Rutherford JC, Taylor WL, Stowasser M & Gordon R. Success of surgery in primary aldosteronism judged by residual autonomous aldosterone production. World Journal of Surgery 1998; 22: 1243-1245.
15. Conn JW. The evolution of primary aldosteronism: 1954-1967. Harvey Lectures 1968; 62: 257-291.
16. Neville AM & O'Hare MJ. Histopathology of the human adrenal cortex. Clinical Endocrinology and Metabolism 1985; 14: 791-820.
17. Tunny TJ, Gordon RD, Klemm SA & Cohn D. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin. Clinical Endocrinology 1991; 34: 363-369.
18. Sutherland DJA, Ruse JL & Laidlaw JC. Hypertension increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Canadian Medical Association Journal 1966; 95: 1109-1119.
19. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265.
20. Pascoe L, Jeunemaitre X, Lebrethon MC et al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. Journal of Clinical Investigation 1995; 96: 2236-2246.
21. Ulick S & Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clinical and Experimental Hypertension 1982; A4: 1771-1777.
22. Gordon RD, Stowasser M, Tunny TJ et al. Clinical and pathological diversity of primary aldosteronism including a new familial variety. Clinical and Experimental Pharmacology and Physiology 1991; 18: 283-286.
23. Stowasser M, Gordon RD, Tunny TJ et al. Familial hyperaldosteronism type II - Five families with a new variety of primary aldosteronism. Clinical and Experimental Pharmacology and Physiology 1992; 19: 319-322.
24. Gordon RD & Stowasser M. Familial forms broaden horizons in primary aldosteronism. Trends in Endocrinology and Metabolism 1998; 9: 220-227.
25. Stowasser M & Gordon RD. Familial hyperaldosteronism. Journal of Steroid Biochemistry and Molecular Biology 2001; 78: 215-229.
26. Stowasser M & Gordon RD. Primary aldosteronism: From genesis to genetics. Trends in Endocrinology and Metabolism 2003; in press.
27. Torpy DJ, Gordon RD, Lin J-P et al. Familial hyperaldosteronism type-II: Description of a large kindred and exclusion of the aldosterone synthase (CYPIIB2) gene. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3214-3218.
28. Torpy DJ, Gordon RD & Stratakis CA. Linkage analysis of familial hyperaldosteronism type II - Absence of linkage of the gene encoding the angiotensin II receptor type I Journal of Clinical Endocrinology and Metabolism 1998; 83: 1046.
29. Lafferty AR, Torpy D, Stowasser M et al. A novel genetic locus for low-renin hypertension: Familial hyperaldosteronism type-II maps to chromosome 7 (7p22). Journal of Medical Genetics 2000; 37: 831-835.
30. Weber KT & Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
31. Rossi GP, Sacchetto A, Pavan E et al. Remodelling of the left ventricular in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471-1478.
32. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology: Heart Circulation Physiology 2002; 283: H1802-H1810.
33. Rossi GP, Sacchetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045.
34. Abe M, Hamada M, Matsuoka H et al. Myocardial scintigraphic characteristics in patients with primary aldosteronism. Hypertension 1994; 23(supplement 1): I-164-I-167.
35. Napoli C, Di Gregorio F, Meccese M et al. Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: The Cross-sectional Primary Aldosteronism and Heart Italian Multicenter Study. Journal of Investigative Medicine 1999; 47: 212-221.
36. Kozakova M, Buralli S, Palombo C et al. Myocardial ultrasonic backscatter in hypertension: Relation to aldosterone and endothelin. Hypertension 2003; 41: 230-236.
37. Murphy BF, Whitworth JA & Kincaid-Smith PA. Malignant hypertension due to an aldosterone-producing adenoma. Clinical and Experimental Hypertension [A] 1985; A7: 939-950.
38. Vetter H, Siebenschein R, Studer A et al. Primary aldosteronism: Inability to differentiate unilateral from bilateral adrenal lesions by various routine clinical and laboratory data and by peripheral plasma aldosterone. Acta Endocrinologica 1978; 89: 710-725.
39. Stowasser M, Gartside MG & Gordon RD. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for Familial Hyperaldosteronism Type I. Australian and New Zealand Journal of Medicine 1997; 27: 685-690.
40. Rich GM, Ulick S, Cook S et al. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Annals of Internal Medicine 1992; 116: 813-820.
41. Stowasser M, Huggard PJ, Rossetti TR et al. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. Journal of Clinical Endocrinology and Metabolism 1999; 84: 4031-4036.
42. Stowasser M. New perspectives in the role of aldosterone excess in cardiovascular disease. Clinical and Experimental Pharmacology and Physiology 2001; 28: 783-791.
43. Gordon RD, Rutherford JC & Stowasser M. Primary aldosteronism: Are we diagnosing and operating on too few patients? World Journal of Surgery 2001; 25: 941-947.
44. Stowasser M & Gordon RD. Primary aldosteronism - Careful investigation is essential and rewarding. Molecular and Cellular Endocrinology 2003; in press.
45. Gordon RD, Storwasser M, Tunny TJ et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology 1994; 21: 315-318.
46. Gordon RD, Ziezak MD, Tunny TJ et al. Evidence that primary aldosteronism may not be uncommon - Twelve percent incidence among antihypertensive drug trial volunteers. Clinical and Experimental Pharmacology and Physiology 1993; 20: 296-298.
47. Brown MA, Cramp HA, Zammit VC & Whitworth JA. Primary aldosteronism: A missed diagnosis in 'essential hypertensives'? Australian and New Zealand Journal of Medicine 1996; 26: 533-538.
48. Nishikawa T & Omura M. Clinical characteristics of primary aldosteronism: Its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomedical Pharmacotherapy 2000; 54(supplement 1): 83s-85s.
49. Gallay BJ, Ahmad S, Xu L et al. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. American Journal of Kidney Diseases 2001; 37: 699-705.
50. Schwartz GL & Turner ST. Predictive value of the aldosterone-renin ratio in screening for primary aldosteronism. American Journal of Hypertension 2002; 15: 226A.
51. Hood S, Cannon J, Scanlon M & Brown MJ. Prevalence of primary hyperaldosteronism measured by aldosterone to renin ratio and spironolactone testing: PHARST study. Journal of Hypertension 2002; 20(supplement 4): S119.
52. Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
53. Gordon RD. Primary aldosteronism. Journal of Endocrinological Investigation 1995; 18: 495-511.
54. Gordon RD. Diagnostic investigations in primary aldosteronism. In Zanchetti A (ed.) Clinical Medicine Series on Hypertension. Maidenhead, UK: McGraw-Hill International, 2001, pp 101-114.
55. Stowasser M, Gordon RD, Rutherford JC et al. Diagnosis management of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System 2001; 2: 156-169.
56. Mulatero P, Rabbia F, Milan A et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
57. Seifarth C, Trenkel S, Schobel H et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clinical Endocrinology 2002; 57: 457-465.
58. Brown MJ & Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgraduate Medical Journal 1999; 75: 235-236.
59. McKenna TJ, Sequeira SJ, Heffernan A et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 1991; 73: 952-957.
60. Gordon RD & Tunny TJ. Aldosterone-producing adenoma (A-P-A): Effect of pregnancy. Clinical and Experimental Hypertension Theory and Practice 1982; A4: 1685-1693.
61. Stowasser M, Gordon RD, Klemm SA & Tunny TJ. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis. Journal of Clinical Endocrinology and Metabolism 1993; 77: 800-804.
62. Litchfield WR & Dluhy RG. Primary aldosteronism. Endocrinology and Metabolism Clinics of North America 1995; 24: 593-612.
63. Holland OB, Brown H, Kuhnert LV et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6: 717-723.
64. Kem DC, Weinberger MH, Mayes DM & Nugent CA. Saline suppression of plasma aldosterone in hypertension. Archives of Internal Medicine 1971; 128: 380-386.
65. Jonsson JR, Klemm SA, Tunny TJ et al. A new genetic test for Familial Hyperaldosteronism Type 1 aids in the detection of curable hypertension. Biochemical and Biophysical Research Communications 1995; 207: 565-571.
66. Stowasser M, Bachmann AW, Jonsson JR et al. Clinical, biochemical and genetic approaches to the detection of Familial Hyperaldosteronism Type 1. Journal of Hypertension 1995; 13: 1610-1613.
67. Mulatero P, Veglio F, Pilon C et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. Journal of Clinical Endocrinology and Metabolism 1998; 83: 2573-2575.
68. Tsushima Y, Ishizaka H & Matsumoto M. Adrenal masses: Differentiation with chemical shift, fast low-angle shot MR imaging. Radiology 1993; 186: 705-709.
69. Vetter H, Fischer M, Galanski M et al. Primary aldosteronism: Diagnosis and noninvasive lateralization procedures. Cardiology 1985; 72(supplement 1): 57.
70. Ganguly AG, Melada GA, Luetscher JA & Dowdy AJ. Control of plasma aldosterone in primary aldosteronism: Distinction between adenoma and hyperplasia. Journal of Clinical Endocrinology and Metabolism 1973; 37: 765-775.
71. Wisgerhof M, Brown RD, Hogan MJ et al. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. Journal of Clinical Endocrinology and Metabolism 1981; 52: 195-198.
72. Gordon RD, Hamlet SM, Tunny TJ & Klemm SA. Aldosterone-producing adenomas responsive to angiotensin pose problems in diagnosis. Clinical and Experimental Pharmacology and Physiology 1987; 14: 175-179.
73. Gordon RD, Gomez-Sanchez CE, Hamlet SM et al. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: Adrenal hyperplasia) or low-renin essential hypertension. Journal of Hypertension 1987; 5(supplement 5): S103-S106.
74. Kem DC, Weinberger MH, Higgins JR et al. Plasma aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension. Journal of Clinical Endocrinology and Metabolism 1978; 46: 552-560.
75. Doppman JL & Gill JR. Hyperaldosteronism: Sampling the adrenal veins. Radiology 1996; 198: 309-312.
76. Stowasser M & Gordon RD. Prevalence and diagnostic workup of primary aldosteronism. Nephrology 2001; 6: 119-126.
77. Lim PO, Dow E, Brennan G et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. Journal of Human Hypertension 2000; 14: 311-315.
78. Nishikawa T, Omura M, Ito H & Saito J. Prevalence of primary aldosteronism among Japanese hypertensive patients. Journal of Hypertension 2002; 20(supplement 4): S172
79. Stowasser M, Klemm SA, Tunny TJ et al. Response to unilateral adrenalectomy for aldosterone-producing adenoma - Effect of angiotensin responsiveness and potassium levels. Clinical and Experimental Pharmacology and Physiology 1994; 21: 319-322.
80. Rutherford JC, Stowasser M, Tunny TJ et al. Laparoscopic adrenalectomy. World Journal of Surgery 1996; 20: 758-760.
81. Lim PO, Jung RT & MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: A prospective cohort follow-up study. British Journal of Clinical Pharmacology 1999; 48: 756-760.
82. Lim PO, Young WF & MacDonald TM. A review of the medical treatment of primary aldosteronism. Journal of Hypertension 2001; 19: 353-361.
83. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
84. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003; 348: 1309-1321.
85. Walker BR & Edwards CRW. Dexamethasone-suppressible hypertension. Endocrinologist 1993; 3: 87-97.
86. Stowasser M, Bachmann AW, Huggard PJ et al. Treatment of familial hyperaldosteronism type 1: Only partial suppression of hybrid gene required to correct hypertension. Journal of Clinical Endocrinology and Metabolism 2000; 85: 3313-3318.